# What Is KLOW Peptide? A Plain-English Overview

> What is KLOW peptide? A plain-English overview of the four-component research blend — KPV, GHK-Cu, BPC-157, and TB-500 — its composition, regulatory status, and what the single-component research has established.

## In plain English

What is KLOW peptide? KLOW peptide is a research-only blend of four separate peptides — small protein fragments — dissolved together in one vial. The four are KPV (an anti-inflammatory tripeptide), GHK-Cu (a copper-carrying matrix peptide), BPC-157 (an angiogenic 15-amino-acid peptide studied in tissue-repair models), and TB-500 (a short fragment of the wound-healing protein thymosin beta-4).

The blend is supplied for research handling only. None of the four components is FDA-approved for human use. The four-peptide combination itself has never been studied in a controlled trial — not in animals, not in humans. All claims about what the blend 'does' are extrapolated from what each individual component was shown to do, separately, mostly in rodents and cells.

One component — TB-500, the thymosin beta-4 fragment — is on the WADA prohibited list, which means competitive athletes face anti-doping consequences from using this blend regardless of intent. That is a regulatory fact, not a theoretical concern.

This page explains what each arm is, how the blend is composed, and what distinguishes KLOW from related blends.

## What is KLOW peptide? — The four-arm composition

KLOW peptide is a co-formulated lyophilized research blend with the following canonical composition (the most widely listed across independent research compounders, not an FDA-approved formulation):

| Component | Mass | Share | Role |
|-----------|------|-------|------|
| GHK-Cu | 50 mg | ~62.5% | Matrix synthesis, copper delivery |
| BPC-157 | 10 mg | 12.5% | Angiogenesis, tissue repair |
| TB-500 | 10 mg | 12.5% | Cytoskeletal mobility, wound closure |
| KPV | 10 mg | 12.5% | Anti-inflammatory, mucosal |

GHK-Cu (Gly-His-Lys copper(II), 402.92 Da, CAS 89030-95-5) is the mass-dominant component at roughly 62.5% of the vial. It is a copper(II) chelate of a tripeptide first isolated from human plasma by Loren Pickart in 1973 [3]. GHK-Cu modulates approximately 31.2% of assayed human genes toward matrix synthesis, antioxidant defense, and DNA repair at low-nanomolar concentrations [2], and stimulates collagen production in placebo-controlled topical human work [3].

BPC-157 (the 15-amino-acid pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, 1419.53 Da, CAS 137525-51-0) is the angiogenic and tissue-repair arm. It activates the VEGFR2 (vascular endothelial growth factor receptor 2) angiogenic pathway and has accelerated Achilles tendon healing in fully transected rat models [4]. A 2025 IV safety pilot in two adults found no adverse events [5].

TB-500 (Ac-LKKTETQ, 889.02 Da) is the synthetic fragment of the actin-binding motif of thymosin beta-4 (Tbeta4). Most efficacy data are for the full-length native protein, not the fragment. Full-length Tbeta4 increased wound re-epithelialization by 42-61% in rat models [6]; in a Phase II RCT, topical Tbeta4 improved dry-eye symptoms [11]. TB-500 is on the WADA prohibited list (S2) [7], [8].

KPV (Lys-Pro-Val, 342.44 Da, CAS 67727-97-3) is the anti-inflammatory arm — the C-terminal tripeptide of alpha-MSH. It is transported into inflamed intestinal epithelial cells via the PepT1 transporter, inhibits NF-kappaB and MAPK inflammatory signaling, and reduced colitis severity in mouse models [1].

## KLOW vs glow

KLOW vs GLOW is the most common distinction question in research-use communities. The difference is the KPV arm: GLOW contains GHK-Cu, BPC-157, and TB-500 but does NOT include KPV. KLOW adds KPV — hence the 'K' in the name — which is the anti-inflammatory tripeptide arm that targets NF-kappaB and mucosal immune signaling via PepT1.

The practical implication is that KLOW has an additional anti-inflammatory layer beyond the angiogenic and cytoskeletal mechanisms the two blends share. Whether adding KPV produces measurably different outcomes has not been tested in any head-to-head comparison study. Community reports describe KLOW as feeling 'more anti-inflammatory' than GLOW, but this is subjective and anecdotal.

Neither KLOW nor GLOW has been tested in a controlled trial. Both are research-only co-formulations.

## Regulatory status — stated plainly

KLOW is not FDA-approved. No component — KPV, GHK-Cu, BPC-157, or TB-500 — has an approved human indication. BPC-157 is in the FDA's category 2 bulk-substances list for 503A compounding, restricting its use in compounded preparations. TB-500/thymosin beta-4 is on the WADA prohibited list (S2, peptide hormones and growth factors), banned at all times in and out of competition [7], [8].

The blend has no controlled-trial evidence. A 2026 Sports Medicine review of unapproved peptide therapies including TB-500 and BPC-157 noted animal-model promise but scarce human safety data, potential for serious harm, and operation largely outside regulatory oversight [7].

None of the four peptides — individually or as KLOW — should be treated as having undergone clinical validation for human use. The research record is the record of what individual components were tested for in controlled laboratory and animal settings.

---

An independent evidence appraisal of four separate research peptide literatures — each finding kept to its own component, the blend's trial column left as the honest blank it is.